Evercore ISI assumed coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a research report released on Wednesday. The firm issued an outperform rating and a $220.00 price objective on the medical research company’s stock.
A number of other equities research analysts have also recently issued reports on the company. Leerink Swann restated an outperform rating and issued a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Zacks Investment Research upgraded Thermo Fisher Scientific from a hold rating to a buy rating and set a $215.00 price objective on the stock in a research note on Tuesday, October 31st. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a buy rating in a research note on Thursday, October 26th. Jefferies Group reiterated a hold rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Finally, Goldman Sachs Group assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a buy rating and a $225.00 price target on the stock. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Thermo Fisher Scientific has a consensus rating of Buy and a consensus price target of $212.21.
Shares of Thermo Fisher Scientific (NYSE:TMO) opened at $202.39 on Wednesday. Thermo Fisher Scientific has a 52 week low of $140.00 and a 52 week high of $202.65. The stock has a market capitalization of $80,730.00, a PE ratio of 34.36, a P/E/G ratio of 1.60 and a beta of 1.06. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at $58,016,113.98. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.49% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Abner Herrman & Brock LLC grew its holdings in shares of Thermo Fisher Scientific by 10.9% during the fourth quarter. Abner Herrman & Brock LLC now owns 32,190 shares of the medical research company’s stock worth $6,112,000 after purchasing an additional 3,159 shares in the last quarter. Washington Trust Bank grew its holdings in shares of Thermo Fisher Scientific by 6.7% during the fourth quarter. Washington Trust Bank now owns 34,032 shares of the medical research company’s stock worth $6,462,000 after purchasing an additional 2,143 shares in the last quarter. Neville Rodie & Shaw Inc. grew its holdings in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Neville Rodie & Shaw Inc. now owns 113,255 shares of the medical research company’s stock worth $21,505,000 after purchasing an additional 1,772 shares in the last quarter. Atlantic Trust Group LLC grew its holdings in shares of Thermo Fisher Scientific by 25.6% during the third quarter. Atlantic Trust Group LLC now owns 710,772 shares of the medical research company’s stock worth $134,480,000 after purchasing an additional 144,924 shares in the last quarter. Finally, AustralianSuper Pty Ltd grew its holdings in shares of Thermo Fisher Scientific by 73.6% during the third quarter. AustralianSuper Pty Ltd now owns 689,898 shares of the medical research company’s stock worth $130,529,000 after purchasing an additional 292,398 shares in the last quarter. 86.22% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3128039/evercore-isi-begins-coverage-on-thermo-fisher-scientific-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.